{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:44:14Z","timestamp":1776012254314,"version":"3.50.1"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,4,12]]},"DOI":"10.7759\/cureus.106893","type":"journal-article","created":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:24:15Z","timestamp":1776011055000},"source":"Crossref","is-referenced-by-count":0,"title":["Pseudo-autologous Stem Cell Transplant for the Treatment of Secondary Central Nervous System Lymphoma"],"prefix":"10.7759","author":[{"given":"Dennis L","family":"Cooper","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Wollowitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jhannine A","family":"Verceles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda","family":"Lombardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mendel","family":"Goldfinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ioannis","family":"Mantzaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amit","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke FL","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, et al.. Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma. N Engl J Med. 2022, 386:640-54. 10.1056\/NEJMoa2116133","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(22)00662-6","article-title":"Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial","volume":"399","author":"Kamdar M","year":"2022","unstructured":"Kamdar M, Solomon SR, Arnason J, et al.. Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet. 2022, 399:2294-308.","journal-title":"Lancet"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov E","year":"2025","unstructured":"Shumilov E, Scholz JK, Seib M, et al.. Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma. Blood Adv. 2025, 9:3955-66. 10.1182\/bloodadvances.2024015719","journal-title":"Blood Adv"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01195-4","article-title":"Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma","volume":"14","author":"Epperla N","year":"2024","unstructured":"Epperla N, Lucero M, Bailey T, et al.. Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma. Blood Cancer J. 2024, 14:210. 10.1038\/s41408-024-01195-4","journal-title":"Blood Cancer J"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtct.2023.09.008","article-title":"Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation analysis","volume":"29","author":"Derigs P","year":"2023","unstructured":"Derigs P, Bethge WA, Kr\u00e4mer I, et al.. Long-term survivors after failure of chimeric antigen receptor T cell therapy for large B cell lymphoma: a role for allogeneic hematopoietic cell transplantation? A German Lymphoma Alliance and German Registry for Stem Cell Transplantation analysis. Transplant Cell Ther. 2023, 29:750-6. 10.1016\/j.jtct.2023.09.008","journal-title":"Transplant Cell Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn LH","year":"2020","unstructured":"Sehn LH, Herrera AF, Flowers CR, et al.. Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma. J Clin Oncol. 2020, 38:155-65. 10.1200\/JCO.19.00172","journal-title":"J Clin Oncol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-022-01582-5","article-title":"Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial","volume":"36","author":"Ferreri AJ","year":"2022","unstructured":"Ferreri AJ, Cwynarski K, Pulczynski E, et al.. Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022, 36:1870-8. 10.1038\/s41375-022-01582-5","journal-title":"Leukemia"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00371-X","article-title":"High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial","volume":"11","author":"Schorb E","year":"2024","unstructured":"Schorb E, Isbell LK, Kerkhoff A, et al.. High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial. Lancet Haematol. 2024, 11:196-205.","journal-title":"Lancet Haematol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30366-5","article-title":"MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial","volume":"8","author":"Ferreri AJ","year":"2021","unstructured":"Ferreri AJ, Doorduijn JK, Re A, et al.. MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial. Lancet Haematol. 2021, 8:e110-21. 10.1016\/S2352-3026(20)30366-5","journal-title":"Lancet Haematol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008525","article-title":"Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients","volume":"7","author":"Cook MR","year":"2023","unstructured":"Cook MR, Dorris CS, Makambi KH, et al.. Toxicity and efficacy of CAR T-cell therapy in primary and secondary CNS lymphoma: a meta-analysis of 128 patients. Blood Adv. 2023, 7:32-9. 10.1182\/bloodadvances.2022008525","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2008.254","article-title":"The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation","volume":"42","author":"Stelljes M","year":"2008","unstructured":"Stelljes M, van Biezen A, Slavin S, et al.. The harvest and use of autologous back-up grafts for graft failure or severe GVHD after allogeneic hematopoietic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 2008, 42:739-42. 10.1038\/bmt.2008.254","journal-title":"Bone Marrow Transplant"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02244.x","article-title":"A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells","volume":"110","author":"Jacquy C","year":"2000","unstructured":"Jacquy C, Sor\u00e9e A, Lambert F, et al.. A quantitative study of peripheral blood stem cell contamination in diffuse large-cell non-Hodgkin's lymphoma: one-half of patients significantly mobilize malignant cells. Br J Haematol. 2000, 110:631-7. 10.1046\/j.1365-2141.2000.02244.x","journal-title":"Br J Haematol"},{"key":"ref13","article-title":"Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: a single-center experience","volume":"72","author":"Takenaka K","year":"2000","unstructured":"Takenaka K, Shinagawa K, Sunami K, et al.. Allogeneic peripheral blood stem cell transplantation in 23 adult patients with hematologic malignancies: a single-center experience. Int J Hematol. 2000, 72:362-70.","journal-title":"Int J Hematol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.11406\/rinketsu.56.428","article-title":"Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation (Article in Japanese)","volume":"56","author":"Hatsuse M","year":"2015","unstructured":"Hatsuse M, Taniguchi-Yoshihara K, Yagyu S, Fuchida S, Okano A, Murakami S, Shimazaki C. Successful treatment with pseudo-autologous blood stem cell transplantation for an adolescent-onset multiple myeloma who relapsed after allogenic bone marrow transplantation (Article in Japanese). Rinsho Ketsueki. 2015, 56:428-31. 10.11406\/rinketsu.56.428","journal-title":"Rinsho Ketsueki"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/MPH.0b013e318241fcf1","article-title":"Rescue by hematopoietic progenitor cells derived from engrafted cord blood unit in a child with brain tumor after transplantation for T-cell acute lymphoblastic leukemia","volume":"34","author":"Jaing TH","year":"2012","unstructured":"Jaing TH, Tseng CK, Mun-Ching Wong A, Lo WC, Wu CT, Ou LS. Rescue by hematopoietic progenitor cells derived from engrafted cord blood unit in a child with brain tumor after transplantation for T-cell acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2012, 34:573-5. 10.1097\/MPH.0b013e318241fcf1","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1038\/bmt.2013.12","article-title":"Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT","volume":"48","author":"Palfreyman E","year":"2013","unstructured":"Palfreyman E, Song K, Nantel S. Pseudo-autologous hematopoietic SCT as treatment for a patient with multiple myeloma who relapsed following an allogeneic hematopoietic SCT. Bone Marrow Transplant. 2013, 48:1138. 10.1038\/bmt.2013.12","journal-title":"Bone Marrow Transplant"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-017-2296-z","article-title":"Pseudo-autologous stem cell transplantation for donor-derived mantle cell lymphoma 12\u00a0years after allogeneic transplantation","volume":"107","author":"Tamaki M","year":"2018","unstructured":"Tamaki M, Wada H, Gomyo A, et al.. Pseudo-autologous stem cell transplantation for donor-derived mantle cell lymphoma 12\u00a0years after allogeneic transplantation. Int J Hematol. 2018, 107:117-21. 10.1007\/s12185-017-2296-z","journal-title":"Int J Hematol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/462342-pseudo-autologous-stem-cell-transplant-for-the-treatment-of-secondary-central-nervous-system-lymphoma","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,12]],"date-time":"2026-04-12T16:24:16Z","timestamp":1776011056000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/462342-pseudo-autologous-stem-cell-transplant-for-the-treatment-of-secondary-central-nervous-system-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,12]]},"references-count":17,"URL":"https:\/\/doi.org\/10.7759\/cureus.106893","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,12]]}}}